Table 1. Phase III trials of fezolinetant in female menopause.

Trial	Setting	Results
Skylight 1 (8)	2019–2021; North America, Europe	Reduced VMS frequency by 51% at 4 weeks, and 61% at 12 weeks from baseline, effect maintained at 52 weeks
Skylight 2 (9)	2019–2021; North America, Europe	Reduced VMS frequency by 55% at 4 weeks, and 64% at 12 weeks from baseline, effect maintained at 52 weeks
Moonlight 3	2020–2023; China	Yet to report
Skylight 4 (10)	2019–2022; North America, Europe	Similar incidence of all treatment-emergent adverse events to placebo at 52 weeks

VMS, vasomotor symptoms.